Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACT trial of fruquintinib plus FTD/TPI in previously treated metastatic colorectal or gastric cancer
jRCT2031240630Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fruquintinib and trifluridine + tipiracil in colorectal adenocarcinoma and gastric adenocarcinoma (3 arms), sponsored by Takeda. Primary endpoints: Incidence of dose-limiting toxicity and Disease control rate. Started Feb 2025; status: active, not recruiting.
02
Drugs
fruquintinibtrifluridine + tipiracil
03
Conditions
colorectal adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on jRCT2031240630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240630.